Articles tagged "Immunosuppression"

2019 American Transplant Congress
Mitochondrial Dysfunction and Metabolic Reprogramming: Critical Features of Cyclosporine A Nephrotoxicity
A. A. Zmijewska, G. Benavides, V. Darley-Usmar, J. W. Zmijewski, R. B. Mannon
University of Alabama at Birmingham, Birmingham, AL
*Purpose: Calcineurin inhibitors (CNIs) are potent immunosuppressants but over time contribute to allograft fibrosis. Clinical efforts to minimize or avoid CNI have not been uniformly…
2019 American Transplant Congress
Risk Factors for 1-5 Year Major Infection Events (MIE) after Kidney Transplant (KTx) Including First-Year Immunosuppression (IS) Data: An Analysis of the Choosing Immune Suppression in Renal Transplantation by Efficacy and Morbidity (CISTEM) Study
V. Dharnidharka¹, D. Axelrod², Z. Zhang³, M. Schnitzler³, K. Lentine³, B. Kasiske⁴
¹Washington Univ, St. Louis, MO, ²Univ of Iowa, Iowa City, IA, ³Saint Louis Univ, St. Louis, MO, ⁴SRTR, Minneapolis, MN
*Purpose: From our CISTEM study of linked national registries, we reported that older recipient age, female sex, diabetic kidney failure, non-standard-criteria organs, and mTORi-based IS…
2019 American Transplant Congress
MDSCs Prolong Allogeneic Cardiac Graft Survival by Regulating Interferon Type 1 Signaling
S. Cai¹, P. T. Sage¹, T. J. Borges¹, T. Ichimura¹, S. K. Eskandari¹, J. Y. Choi¹, I. Salkuj¹, B. S. AI Dulaijan¹, H. Allos¹, J. Miao², L. V. Riella¹, A. K. Chandraker¹, J. R. Azzi¹
¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Boston Children's Hospital, Harvard Medical School, Boston, MA
*Purpose: We previously demonstrated that donor-derived regulatory dendritic cells (DCreg), contrary to recipient derived DCreg, promote antigen-specific allograft protection. As myeloid-derived suppressor cells (MDSC) show…
2019 American Transplant Congress
Implementation of a De Novo Belatacept Protocol
D. Wojciechowski¹, M. Jacobs², K. Safa¹, H. Gilligan¹, H. Eliot¹, W. W. Williams, Jr¹
¹Massachusetts General Hospital, Boston, MA, ²Wake Forest, Winston-Salem, NC
*Purpose: The use of belatacept with basiliximab induction and maintenance MMF/prednisone when compared to cyclosporine is associated with superior long-term patient and graft survival but…
2019 American Transplant Congress
Belatacept Use in High Kidney Donor Profile Index Kidney Transplant Recipients
D. Britt¹, A. Gharabagi¹, K. Botkin¹, T. Horwedel², C. Carthon¹, J. Hagopian¹
¹Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, ²Veloxis Pharmaceuticals, Cary, NC
*Purpose: To determine whether the use of belatacept is associated with renal function preservation in kidney transplant recipients from donors with a kidney donor profile…
2019 American Transplant Congress
ICOS⁺PD-1⁺ Circulating T Follicular Helper Cells Are a Biomarker of Humoral Alloreactivity and Predict Donor-Specific Antibody Generation Following Transplantation
G. M. La Muraglia II, M. E. Wagener, M. L. Ford, I. R. Badell
Emory Transplant Center, Atlanta, GA
*Purpose: Mounting evidence in kidney transplantation suggests that donor-specific antibodies (DSA) significantly contribute to renal allograft loss. However, biomarkers to guide clinical management of DSA…
2019 American Transplant Congress
Anti-Complement Component 5 Antibody Based Immunosuppression Induced Accommodation in ABO Incompatible Heart Transplantation
S. Park¹, S. Lee¹, J. Hwang¹, J. Ryu², T. Koo², C. Ahn³, J. Yang⁴
¹Biomedical Research Institute, Seoul National University Hospital, Seoul, Korea, Republic of, ²Transplantation Center, Seoul National University Hospital, Seoul, Korea, Republic of, ³Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of, ⁴Department of Surgery, Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: Plasmapheresis in combination with immunoglobulin and rituximab is often used to induce accommodation in ABO-incompatible (ABOi) living-donor transplantation; however, this regimen cannot be applied…
2019 American Transplant Congress
Racial Disparities in Documentation of Non-Adherence and Its Relation to Rejection in Pediatric Kidney Transplant Recipients
T. Melanson, J. Hogan, K. Maroney, R. Patzer, R. George
Emory University, Atlanta, GA
*Purpose: Black patients have historically been disadvantaged throughout the transplant process. Many factors impact the success of kidney transplantation, but the need for strict adherence…
2019 American Transplant Congress
Assessing the Effectiveness of Early Maintenance Immunosuppression Practices in Liver Transplantation
T. Bittermann, R. Hubbard, J. Lewis, D. Goldberg
University of Pennsylvania, Philadelphia, PA
*Purpose: Evidence regarding the efficacy of maintenance immunosuppression (IS) regimens for liver transplantation (LT) arise from clinical trials. However, the ‘real world’ effectiveness of such…
2019 American Transplant Congress
Prevalence of Non-Adherence to Immunosuppressive Medications in Kidney Transplant Recipients, Barriers and Predictors
S. Taj¹, H. Baghaffar², D. Alnajjar², N. Almashabi³, S. Ismail⁴
¹King Saud Bin Abdulaziz University For Health Sciences, Jeddah, Saudi Arabia, ²Ibn Sina College, Jeddah, Saudi Arabia, ³Umm Al-Qura University, Makkah, Saudi Arabia, ⁴Pharmaceutical Care Department, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
*Purpose: Non-adherence to immunosuppressant therapy (IST) is one of the major factors leading to graft rejection. To our knowledge, limited data exist on the prevalence…